arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Alaunos Therapeutics, Inc.

TCRT
$1.97 ▼ -0.03 (-1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alaunos Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.8M
Dividend Yield
Revenue Growth -50.0%
Op. Margin None
ROIC -155.0%
FCF / Share $-1.52
Trailing P/E
Price / Book 2.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.00K
↓ -50.0%
Net Income Profit after all expenses
$-4.18M
↑ +10.8%
FCF / Share Free cash flow per share
$-1.52
↑ +50.9%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
3
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 23 years · 73 quarters